Markets

Insider Trading

Hedge Funds

Retirement

Opinion

STMicroelectronics N.V. (STM): Among The 10 Oversold Blue Chip Stocks to Buy Now

We recently compiled a list of the 10 Oversold Blue Chip Stocks to Buy NowIn this article, we are going to take a look at where STMicroelectronics N.V. (NYSE:STM) stands against other oversold blue chip stocks.

Market experts believe that, so far, 2024 continues to be a strong year for the broader stock market. With the predictions of rate cuts, some strategists opine that next year can be another year for the equities. On a YTD basis, the S&P 500 saw an increase of over ~22%. On a related note, Fidelity Investments (in the note dated October 16, 2024) highlighted that equities rallied in Q3 2024, courtesy of real estate, US value, and some small-cap stocks. While volatility increased in August, it decreased later. This led to a productive September.

Fidelity Investments went on to say that the US labor market demonstrated signs of cooling. However, it remained strong overall. Despite some softness in manufacturing, some of the major global economies continued to expand. Elsewhere, in China, new policies to fuel stock prices were rolled out. While the positive impact was seen in the Chinese equities post the stimulus measures, there remains some uncertainty regarding the long-term impact.

Factors to Watch Out For in 2025

With 2024 approaching an end, global investors continue to wonder about the factors that might influence the broader financial markets in 2025. The markets are intertwined, making US stocks more sensitive to several factors. Forbes reported that the results of the 2024 presidential election, domestic inflation and rates, technology innovation, economic trends, and elevated geopolitical tensions are some of the factors likely to influence the financial markets

As per TradingBlock, the tariff measures, together with a national deficit, are some of the critical issues for the next president. While the new tariffs can slow down the broader US economy, the deficit, if left unchecked, might lead to continued devaluation of the U.S. dollar. Also, a slowdown of the US economy might result in inflation worries.

Some market experts continue to worry about the Chinese economy. As per SALT Venture Group, the slowness in China can be a constraint for the stock market growth in the next year. This is because this slowdown can weaken the demand for US exports. As per CEIC, the US total exports to China sat at ~$12.618 billion in August 2024.

READ ALSO: 7 Best Stocks to Buy For Long-Term and 8 Cheap Jim Cramer Stocks to Invest In.

What to Expect from the Stock Market in 2025?

Forbes reported that experts are predicting stock market growth to vary in the range of a 5% decline to growth of 20% in 2025. However, some experts believe that a 10% increase is expected to be the most likely scenario. UBS expects that the stock market is on track for another year of double-digit gains. The strategists made a bullish call for stocks, projecting that the S&P 500 is expected to touch 6,600 by next year’s end. The firm went on to add that the increase is expected to be aided by a “no landing” for the economy.

The improved US macroeconomic outlook has increased the bank’s degree of certainty about the positive view of equities. Notably, the job market continues to be resilient amidst tighter financial conditions and elevated interest rates. Investors might witness some volatility because of the November election, but it’s unlikely that it will be a hurdle to more positive market drivers.

A financial analyst at his computer monitor, tracking the public company’s investments.

Our Methodology

To list the 10 Oversold Blue Chip Stocks to Buy Now, we extracted the companies that have a market cap of over $10 billion by using a Finviz screener. After getting an initial list of 25-30 stocks, we chose the ones trading at a forward P/E multiple of less than 15.0x and which have fallen significantly on a YTD basis. Finally, the stocks were ranked in the ascending order of their hedge fund sentiments, as of Q2 2024.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

STMicroelectronics N.V. (NYSE:STM)

Market cap (As of 25 October): $25.4 billion

Forward P/E (As of 25 October): 10.52x

% Decline on a YTD Basis: ~41%

Number of Hedge Fund Holders: 16

STMicroelectronics N.V. (NYSE:STM) is engaged in designing, developing, manufacturing, and selling semiconductor products in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.

STMicroelectronics N.V. (NYSE:STM) announced the construction of a new high-volume silicon carbide manufacturing facility in Italy, which is supported by significant investment and state support. Wall Street analysts opine that the company’s gross margins should improve in the upcoming quarters because of a better mix and reduced loading costs. Moving forward, the growth in components related to electric vehicles is expected, primarily in China.

STMicroelectronics N.V. (NYSE:STM) remains focused on converting to 300-millimeter and 200-millimeter silicon-based technology. STMicroelectronics N.V. (NYSE:STM) and Qualcomm Technologies International, Ltd. announced a new strategic collaboration for the next generation of industrial and consumer loT solutions augmented by edge Al. This partnership focuses on integrating Qualcomm’s wireless connectivity solutions with STMicroelectronics’ STM32 microcontroller ecosystem. The products from this collaboration should be available to OEMs in Q1 2025.

Despite the challenging environment, Wall Street analysts remain optimistic about the long-term trends in the automotive sector, and the outlook of silicon carbide technology. Collectively, these factors place STMicroelectronics N.V. (NYSE:STM) well for long-term growth. The company is introducing its fourth-generation STPOWER silicon carbide (SiC) MOSFET technology.

While serving the automotive and industrial markets, this technology is particularly optimized for traction inverters, which is a critical component of EV powertrains. The company focuses on introducing further advanced SiC technology innovations through 2027 as a commitment to innovation. Wall Street believes that the shares of STMicroelectronics N.V. (NYSE:STM) have an average price target of $42.00.

Overall STM ranks 8th on our list of 10 Oversold Blue Chip Stocks to Buy Now. While we acknowledge the potential of STM as an investment, our conviction lies in the belief that some deeply undervalued AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for a deeply undervalued AI stock that is more promising than STM but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.

Disclosure: None. This article is originally published at Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

Penicillin Changed the World. This Drug Could Too

This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses Including a single drug to treat COVID, RSV, FLU and even Monkey-pox!

This is a clinical-stage, global leader in broad-spectrum antiviral nanomedicines who is developing therapeutic drugs that work safely and effectively, even against emerging variants!

A novel broad-spectrum antiviral

NV-387,  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, the company has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Click to continue reading…